Christopher Pinahs Joins Robins Kaplan’s Intellectual Property and Technology Group
April 14, 2017
Christopher Pinahs recently joined Robins Kaplan LLP’s Intellectual Property and Technology Litigation Group, where he focuses his practice on patent and trademark litigation. Applying his background in the biological sciences, Pinahs has extensive experience representing clients in the pharmaceutical, medical device, and agricultural arts. In all arenas, Pinahs uses his technical background to help clients develop their case and implement an appropriate strategy to achieve their business goals.
Pinahs’ trial experience includes several significant cases in the health and life sciences industry, including the representation of a generic manufacturer in its challenge of several patents directed to Purdue’s multibillion-dollar OxyContin® product. More recently, Pinahs was a member of a trial team that prevailed on several patents directed to the Alzheimer’s drug, Namenda XR®.
While attending classes at the University of Minnesota Law School, Pinahs simultaneously studied to earn his master’s degree in plant biological studies. He received his J.D. in 2011, and his M.S. in 2012.
Pinahs is active in the legal community, and his involvement includes pro bono representation through the Pro Se Project. He previously served as the chair of the Intellectual Property Practice Group for the Minnesota Federal Bar Association (2015-2016), and currently serves as a member of the Grants Committee for the Minnesota Federal Bar Association.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.